(Q61924442)

English

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Phase 1 Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Advanced B-Lymphoid Malignancies (English)

0 references

medical condition

multiple myeloma

0 references

sponsor

Sunesis Pharmaceuticals

0 references

country

United States of America

0 references

main subject

hematologic cancer

0 references

start time

February 2007

0 references

end time

December 2008

0 references

number of participants

21

0 references

clinical trial phase

phase I clinical trial

0 references

research site

University of Texas at Houston Police Department

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT00446342

0 references

(Q61924442)

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)